Related Experiment Video
Updated: Feb 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
E David Crawford1, Axel Heidenreich2,3, Nathan Lawrentschuk4
1University of Colorado School of Medicine, Denver, CO, USA. David.Crawford@UCDenver.edu.
Androgen deprivation therapy (ADT) for advanced prostate cancer (PCa) has advanced significantly. Lowering testosterone (T) to <20 ng/dL improves survival, with new therapies enhancing T suppression and patient outcomes.
Area of Science:
- Oncology
- Urology
- Endocrinology
Background:
- Androgen deprivation therapy (ADT) is a cornerstone for advanced prostate cancer (PCa).
- Recent scientific breakthroughs have revolutionized ADT, including new therapies and diagnostic tools.
- Understanding testosterone (T) suppression targets and genetic mutations is crucial.
Purpose of the Study:
- To review current Androgen deprivation therapy (ADT) options for advanced prostate cancer (PCa).
- To outline best practices for managing patients undergoing ADT.
- To discuss future therapeutic directions in advanced PCa.
Main Methods:
- Review of clinical profiles of up-to-date ADT options.
- Discussion of best practices in patient management.
- Exploration of future therapeutic strategies.
Main Results:
- Modern assays define castration as serum T <15 ng/dL, lower than the historical <50 ng/dL.
- Evidence supports lowering T to <20 ng/dL for improved survival and delayed progression in advanced PCa.
- New combination therapies and T suppression monitoring enhance treatment efficacy.
Conclusions:
- Personalized ADT regimens are essential, considering initiation, duration, and monitoring of T and PSA.
- Switching therapies and intermittent vs. continuous ADT should be tailored to individual patient factors.
- Optimizing ADT strategies, including T suppression targets and combination therapies, significantly improves outcomes for advanced prostate cancer.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Design Consideration
The factor of safety is another key...
Tensile Strength Considerations of Concrete
The dimensions and shape of a concrete specimen...
Transmission Line Design Considerations
Gene Therapy

